DMAC News and Press, DiaMedica Therapeutics Inc. From 07/07/22

Gainers: Longeveron ( LGVN ) +16% . Adverum Biotechnologies ( ADVM ) +13% . 89bio ( ETNB ) +12% . Mainz Biomed ( MYNZ ) +11% . Shineco ( SISI ) +8% . Losers: DiaMedica Therapeutics ( DMAC ) -41% . Cytom...

DiaMedica Therapeutics ( DMAC ) -35% after FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold . CytomX Therapeutics ( CTMX ) -27% on phase 2 study of breast cancer antibody praluzatamab . Yatsen Holding ( YSG ) -1...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 19th Annual Craig-Hallum Institutional Investor Conference b...

The following slide deck was published by DiaMedica Therapeutics Inc. in conjunction with their 2022 Q1 earnings call. For further details see: DiaMedica Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation

DiaMedica Therapeutics Inc. (DMAC) Q1 2022 Earnings Conference Call May 05, 2022 08:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alexander Nowak -...

DiaMedica Therapeutics press release (NASDAQ:DMAC): Q1 GAAP EPS of -$0.13 beats by $0.07. For further details see: DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.07

Conference Call and Webcast May 5 at 8:00 am Eastern Time / 7:00 am Central Time Continuing to Expand Clinical Study Sites in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Cash Runway Into 2024 DiaMedica Therapeutics Inc. (Nasdaq: ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2022 financial results will be released after the markets close on Wednesd...

DiaMedica Therapeutics Inc. (DMAC) Q4 2021 Earnings Conference Call March 15, 2022 08:00 AM ET Company Participants Rick Pauls - President & Chief Executive Officer Kirsten Gruis - Chief Medical Officer Dominic Cundari - Chief Commercial Officer Scott Kellen - Chief Financial Officer Conf...

DiaMedica Therapeutics press release (NASDAQ:DMAC): FY GAAP EPS of -$0.65 beats by $0.08. As of December 31, 2021, DiaMedica had cash, cash equivalents and marketable securities of $45.1 million, working capital of $43.9 million and shareholders’ equity of $44.0 million, compared to $2...